Financing channel feed

Valen­z­aBio's on­col­o­gy is­land of mis­fit toys snares $70M af­ter toil­ing be­hind the scenes for months

5 years ago

Fe­male en­tre­pre­neurs have long been un­der­rep­re­sent­ed in biotech. An MIT team de­cid­ed to find out why

5 years ago
People

Eli Cas­din and Kei­th Meis­ter dive back in­to the SPAC well with $480M haul just weeks af­ter So­ma­Log­ic re­verse merg­er

5 years ago

Ver­sant-backed Ven­tus scores $100M round to tur­bocharge its dual-plat­form play at 'drug­ging the un­drug­gable'

5 years ago

Icosavax keeps up the ex­cite­ment for its VLP 'soc­cer balls,' earn­ing the RA Cap­i­tal stamp of ap­proval in $100M Se­ries B

5 years ago
Coronavirus

Min­eralys emerges with a new take on an old idea for the treat­ment of hy­per­ten­sion and $40M to play with

5 years ago

With fresh in­vestor cash in hand, Volas­tra part­ners with Mi­crosoft to de­vel­op metasta­t­ic can­cer bio­mark­er plat­form

5 years ago
Deals
AI

Hav­ing shipped its first bench­top gene edit­ing de­vices, In­scrip­ta draws an­oth­er $150M from deep in­vestor well

5 years ago

Rain Ther­a­peu­tics head­lines newest slate of IPO-bound biotechs with $100M pen­ciled in for lead on­col­o­gy pro­gram

5 years ago

Pe­ter Thiel jumps aboard Al­loy's lat­est $75M round, adding some heft to the an­ti­body dis­cov­ery out­fit's nascent plat­form

5 years ago

Why do some tar­get­ed can­cer ther­a­pies stop work­ing? For Tyra, that's the $106M ques­tion

5 years ago

Scribe, Jen­nifer Doud­na's newest start­up, nabs a mega-round and a vo­cal in­vestor

5 years ago

A pair of Lyell founders look to shift the cell ther­a­py par­a­digm — and they've got $30M to get their plan off the ground

5 years ago
Cell/Gene Tx

Bet­ting ear­ly on an AI niche, RA Cap­i­tal seeds a young founder's quest to un­lock 'Holy Grail' tar­gets

5 years ago
Startups
AI

Piv­ot­ing to­ward neu­ro­mus­cu­lar dis­eases and Duchenne, En­tra­da locks down $116M crossover round

5 years ago

Armed with Pfiz­er's ADC plat­form, Pyx­is scores $152M round to shoot for the clin­ic while tak­ing its time on I/O pro­grams

5 years ago

Go­ing head-to-head with Mer­ck on I/O, Genen­tech vets raise fresh round and en­ter clin­ic

5 years ago

Flag­ship start­up Omega takes lead 'epige­nom­ic con­troller' can­di­date clos­er to the clin­ic with new $126M round

5 years ago

Af­ter tack­ling Covid-19 with As­traZeneca, Ox­ford's Jen­ner In­sti­tute is hard at work on a dif­fer­ent kind of vac­cine

5 years ago

It's a brave new world for So­ma­Log­ic, as the pro­teomics biotech rides Eli Cas­d­in's newest SPAC to Nas­daq with $1.2B val­u­a­tion

5 years ago
Deals

With an­oth­er $148M in the bank, Gy­ro­scope Ther­a­peu­tics looks to hus­tle its AMD gene ther­a­py through mid-stage tests

5 years ago

An­oth­er 4 phar­mas make the fa­bled Nas­daq leap, with com­bined raise rapid­ly ap­proach­ing $4.5B

5 years ago

GV wa­gers on sea­soned team's in­tranasal 'tem­po­rary' pre­ven­ta­tive ap­proach to virus­es — with ex-Gilead CEO John Mar­tin jump­ing on board

5 years ago
Startups

River­Vest off to the races with $275M to in­vest in ear­ly-stage biotech

5 years ago
First page Previous page 78798081828384 Next page Last page
A service from the Financial Times